These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 11100963)

  • 1. Type I, II, III, IV, and V cystic fibrosis transmembrane conductance regulator defects and opportunities for therapy.
    Choo-Kang LR; Zeitlin PL
    Curr Opin Pulm Med; 2000 Nov; 6(6):521-9. PubMed ID: 11100963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy.
    Kerem E
    Pediatr Pulmonol; 2005 Sep; 40(3):183-96. PubMed ID: 15880796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis.
    Sloane PA; Rowe SM
    Curr Opin Pulm Med; 2010 Nov; 16(6):591-7. PubMed ID: 20829696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of protein repair therapy in the treatment of cystic fibrosis.
    Rubenstein RC; Zeitlin PL
    Curr Opin Pediatr; 1998 Jun; 10(3):250-5. PubMed ID: 9716885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Functional characterization of naturally occurring CFTR mutants: interest for cystic fibrosis].
    Romey MC
    Ann Biol Clin (Paris); 2006; 64(5):429-37. PubMed ID: 17040873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repairing the basic defect in cystic fibrosis - one approach is not enough.
    Farinha CM; Matos P
    FEBS J; 2016 Jan; 283(2):246-64. PubMed ID: 26416076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapy for cystic fibrosis: cystic fibrosis transmembrane conductance regulator mutation-specific pharmacologic strategies.
    Rubenstein RC
    Mol Diagn Ther; 2006; 10(5):293-301. PubMed ID: 17022692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
    Solomon GM; Marshall SG; Ramsey BW; Rowe SM
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics of cystic fibrosis treatment.
    Carter SC; McKone EF
    Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting CFTR: how to treat cystic fibrosis by CFTR-repairing therapies.
    Amaral MD
    Curr Drug Targets; 2011 May; 12(5):683-93. PubMed ID: 21039334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new era of personalized medicine for cystic fibrosis - at last!
    Quon BS; Wilcox PG
    Can Respir J; 2015; 22(5):257-60. PubMed ID: 26083544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel, mechanism-based therapies for cystic fibrosis.
    Rubenstein RC
    Curr Opin Pediatr; 2005 Jun; 17(3):385-92. PubMed ID: 15891431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging drug treatments for cystic fibrosis.
    Zeitlin PL
    Expert Opin Emerg Drugs; 2003 Nov; 8(2):523-35. PubMed ID: 14662004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cystic fibrosis: molecular update and clinical implications].
    Orozco L; Chávez M; Saldaña Y; Velázquez R; Carnevale A; González-del Angel A; Jiménez S
    Rev Invest Clin; 2006; 58(2):139-52. PubMed ID: 16827266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fixing cystic fibrosis by correcting CFTR domain assembly.
    Okiyoneda T; Lukacs GL
    J Cell Biol; 2012 Oct; 199(2):199-204. PubMed ID: 23071149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Protein repair therapy in cystic fibrosis].
    Clément A; Tamalet A; Fauroux B; Epaud R
    Rev Prat; 2003 Jan; 53(2):163-6. PubMed ID: 12664848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein.
    Brown CR; Hong-Brown LQ; Biwersi J; Verkman AS; Welch WJ
    Cell Stress Chaperones; 1996 Jun; 1(2):117-25. PubMed ID: 9222597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.
    Bell SC; De Boeck K; Amaral MD
    Pharmacol Ther; 2015 Jan; 145():19-34. PubMed ID: 24932877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New and emerging targeted therapies for cystic fibrosis.
    Quon BS; Rowe SM
    BMJ; 2016 Mar; 352():i859. PubMed ID: 27030675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.